Morgan Stanley analyst Sean Laaman has maintained their bullish stance on JAZZ stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sean Laaman has given his Buy rating due to a combination of factors including the promising clinical trial results for Jazz Pharmaceuticals’ drug Zepzelca. The Phase 3 IMforte study demonstrated that Zepzelca, when combined with atezolizumab, significantly improved progression-free survival and overall survival in patients with extensive-stage small cell lung cancer compared to atezolizumab alone. This combination therapy reduced the risk of disease progression or death by 46%, showcasing its potential to become a new standard of care.
Additionally, the safety profile of the combination was highlighted, with most adverse events being manageable and a low discontinuation rate due to side effects. The positive reception of Zepzelca by key opinion leaders and its potential inclusion in NCCN guidelines suggest a broader adoption and reimbursement in the near future. These factors, along with the expectation of rapid adoption by physicians and its contribution to Jazz Pharmaceuticals’ revenue, underpin Laaman’s optimistic outlook on the stock.
Laaman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Exelixis, and Halozyme. According to TipRanks, Laaman has an average return of 3.3% and a 56.97% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $202.00 price target.